Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17051
Title: Magnesium supplementation: pharmacokinetics in cardiac surgery patients with normal renal function
Authors: Biesenbach, Peter;Mårtensson, Johan;Osawa, Eduardo;Eastwood, Glenn M;Cutuli, Salvatore;Fairley, Jessica;Matalanis, George;Bellomo, Rinaldo
Affiliation: Department of Intensive Care, Austin Health, Heidelberg, Melbourne, Australia
Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, Sweden.
Intensive Care Unit, Warringal Private Hospital, Heidelberg, Victoria, Australia
School of Public Health and Preventive Medicine, Monash University, Prahran, Victoria, Australia.
Department of Cardiac Surgery, Austin Health, Heidelberg, Melbourne, Australia.
Intensive Care Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Issue Date: 11-Jan-2018
EDate: 2018
Citation: Journal of critical care 2018; 44: 419-423
Abstract: Intravenous magnesium is routinely administered in intensive care units (ICU) to treat arrhythmias after cardiothoracic surgery. There are no data on the pharmacokinetics of continuous magnesium infusion therapy. To investigate the pharmacokinetics of continuous magnesium infusion, focusing on serum and urinary magnesium concentration, volume of distribution and half-life. We administered a 10 mmol bolus of magnesium-sulfate followed by a continuous infusion of 3 mmol/h for 12 h in twenty cardiac surgery patients. We obtained blood and urine samples prior to magnesium administration and after one, six, and 12 h. Median magnesium levels increased from 1.09 (IQR 1.00-1.23) mmol/L to 1.59 (1.45-1.76) mmol/L after 60 min (p < .001), followed by 1.53 (1.48-1.71) and 1.59 (1.48-1.76) mmol/L after 6 and 12 h. Urinary magnesium concentration increased from 9.2 (5.0-13.9) mmol/L to 17 (13.6-21.6) mmol/L after 60 min (p < .001). Cumulative urinary magnesium excretion was 28 mmol (60.9% of the dose given). The volume of distribution was 0.25 (0.22-0.30) L/kg. There were no episodes of severe hypermagnesemia (≥3 mmol/L). Combined bolus and continuous magnesium infusion therapy leads to a significant and stable increase in magnesium serum concentration despite increased renal excretion and redistribution.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17051
DOI: 10.1016/j.jcrc.2018.01.011
ORCID: 0000-0002-1650-8939
PubMed URL: 29353118
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29353118
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.